Trends in development of treatment guidelines for multidrug-resistant tuberculosis

doi:10.3969/j.issn.1000-6621.2018.02.004

Abstract

Abstract:

The global incidence of tuberculosis has declined marginally from 2000 to 2017, but it is still under poor control in parts of Africa and Asia. Multidrug-resistant tuberculosis (MDR-TB) has become a major concerned issue in the global public health system, and the optimum medications and treatment regimens for MDR-TB remain controversial. This review summarizes the treatment guidelines for MDR-TB in recent years and analyzes the background, specific recommendations, implementations and trends of these guidelines.

Key words: Tuberculosis, multidrug-resistant, Guidebooks, Drug therapy, combination, Therapeutic uses, Comment

Yi ZHANG,Feng SUN,Wen-hong. ZHANG. Trends in development of treatment guidelines for multidrug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2018, 40(2): 135-139. doi: 10.3969/j.issn.1000-6621.2018.02.004

References 32

[1]	World Health Organization . Global tuberculosis report 2017. Geneva: World Health Organization, 2017.
[2]	World Health Organization . Guidelines for establishing DOTs-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). Geneva: World Health Organization, 2000.
[3]	World Health Organization . Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2006.
[4]	World Health Organization . Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2011. pmid: 21828024
[5]	WHO Guidelines Approved by the Guidelines Review Committee. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016. URL pmid: 27748093
[6]	International Union Against Tuberculosis and Lung Disease . Guidelines for the clinical and operational management of drug-resistant tuberculosis. Paris: International Union Against Tuberculosis and Lung Disease, 2013.
[7]	Pablos-Méndez A, Raviglione MC, Laszlo A , et al. Global surveillance for antituberculosis-drug resistance, 1994—1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med, 1998,338(23):1641-1649. doi: 10.1056/NEJM199806043382301 URL
[8]	Mitnick C, Bayona J, Palacios E , et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med, 2003,348(2):119-128. doi: 10.1056/NEJMoa022928 URL pmid: 12519922
[9]	Leimane V, Riekstina V, Holtz TH , et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet, 2005,365(9456):318-326. doi: 10.1016/S0140-6736(05)70196-3 URL
[10]	World Health Organization . Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2008.
[11]	World Health Organization . Treatment of tuberculosis: guidelines for national programs. Geneva:World Health Organization, 2003.
[12]	Shah NS, Wright A, Bai GH , et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis, 2007,13(3):380-387. doi: 10.3201/eid1303.061400 URL pmid: 2725916
[13]	Gandhi NR, Moll A, Sturm AW , et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet, 2006,368(9547):1575-1580. doi: 10.1016/S0140-6736(06)69573-1 URL
[14]	World Health Organization . Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva:World Health Organization, 2010.
[15]	Johnston JC, Shahidi NC, Sadatsafavi M , et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One, 2009,4(9):e6914. doi: 10.1371/journal.pone.0006914 URL pmid: 19742330
[16]	Malla P, Kanitz EE, Akhtar M , et al. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. PLoS One, 2009,4(12):e8313. doi: 10.1371/journal.pone.0008313 URL
[17]	Orenstein EW, Basu S, Shah NS , et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systema-tic review and meta-analysis. Lancet Infect Dis, 2009,9(3):153-161. doi: 10.1016/S1473-3099(09)70041-6 URL
[18]	World Health Organization . The WHO end TB strategy. Geneva:World Health Organization, 2015.
[19]	World Health Organization . Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva:World Health Organization, 2014.
[20]	Xia Q, Zhao LL, Li F , et al. Phenotypic and genotypic chara-cterization of pyrazinamide resistance among multidrug-resis-tant Mycobacterium tuberculosis isolates in Zhejiang, China. Antimicrob Agents Chemother, 2015,59(3):1690-1695. doi: 10.1128/AAC.04541-14 URL
[21]	Pang Y, Zhang Z, Wang Y, et al. Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China , 2000 to 2010. Antimicrob Agents Chemother, 2017, 61(2). pii:e02170-16.
[22]	Aung KJ, Van Deun A, Declercq E , et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis, 2014,18(10):1180-1187. doi: 10.5588/ijtld.14.0100 URL
[23]	Kuaban C, Noeske J, Rieder HL , et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis, 2015,19(5):517-524. doi: 10.5588/ijtld.14.0535 URL pmid: 25868018
[24]	Piubello A, Harouna SH, Souleymane MB , et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis, 2014,18(10):1188-1194. doi: 10.5588/ijtld.13.0075 URL
[25]	Van Deun A, Maug AK, Salim MA , et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010,182(5):684-692. doi: 10.1164/rccm.201001-0077OC URL
[26]	World Health Organization . The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents. Geneva:World Health Organization, 2016.
[27]	World Health Organization . The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Geneva:World Health Organization, 2013.
[28]	Javaid A, Ahmad N, Khan AH , et al. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. Eur Respir J , 2017, 49(1). pii: 1601967. doi: 10.1183/13993003.01967-2016 URL
[29]	Ruan Q, Liu Q, Sun F , et al. Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of rando-mized clinical trials. Emerg Microbes Infect, 2016,5:e12. doi: 10.1038/emi.2016.12 URL
[30]	Sotgiu G, Tiberi S, D’Ambrosio L , , et al. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis. Eur Respir J, 2016,48(5):1503-1507. doi: 10.1183/13993003.01249-2016 URL pmid: 27587544
[31]	Tiberi S, Payen MC, Sotgiu G , et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J, 2016,47(4):1235-1243. doi: 10.1183/13993003.02146-2015 URL
[32]	Magis-Escurra C, Günther G, Lange C , et al. Treatment outcomes of MDR-TB and HIV co-infection in Europe. Eur Respir J, 2017, 49 (6). pii: 1602363. doi: 10.1183/13993003.02363-2016 URL pmid: 28596434